Novo Partners with Anthropic to Speed up Drug Development with Claude
Novo will test Claude Science in research workflows and automate trial reporting as drugmakers increasingly turn to AI, the companies said.
- On Sept 16, Novo Nordisk partnered with Anthropic to utilize Claude models for accelerating medicine discovery and development. The Danish drugmaker will initially test Anthropic models and Claude Science in research and development workflows.
- Drugmakers are increasingly adopting artificial intelligence to accelerate research pipelines. The Wegovy maker intends to leverage Anthropic frontier models to strengthen AI-driven software development.
- Novo already utilizes Claude to automate trial report generation, successfully trimming timelines for patient documentation from months to minutes.
- "AI tools can also offer completely new scientific opportunities," Novo CEO Mike Doustdar said. Anthropic CEO Dario Amodei noted frontier models can shorten research timelines and improve outcomes.
- Industry leaders remain split over how rapidly companies should develop next-generation technology, even as the agreement underscores growing integration of advanced models across the pharmaceutical sector.
38 Articles
38 Articles
DANISH pharmaceutical company Novo, the maker of Ozempic, has partnered with AI company Anthropic to accelerate the development of new drugs using the Claude artificial intelligence model.
Anthropic and Ozempic's developer announce AI drug discovery collaboration
Danish pharmaceutical company Novo Nordisk is partnering with American artificial intelligence company Anthropic, aiming to use Anthropic’s Claude model to advance its drug discovery research and development. Novo, the developer of the popular weight loss drug Ozempic, announced the partnership on Wednesday, saying it will help the company in its mission to become “the world’s […]
Novo teams up with Anthropic to speed up drug discovery
“Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,” said Mike Doustdar, president and chief executive of Novo. The Danish drugmaker, formerly branded Novo Nordisk, and Anthropic announced a collaboration on 16 September, according to Novo’s announcement. […] This story continues at The Next Web
Coverage Details
Bias Distribution
- 48% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
